Results 31 to 40 of about 53,142 (237)
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Medical Laboratory Journal, 2022 Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by the accumulation of large amounts of fat in the hepatocytes.
Zahra Eslami +8 more
doaj
Direct Regioselective para‐Fluorination via I(I)/I(III) Catalysis
Angewandte Chemie, EarlyView.A direct, para‐selective fluorination by I(I)/I(III) catalysis is disclosed that does not require substrate pre‐functionalization. This strategy leverages the Leonard link inherent to phenylpropanoate and phenylpropanamides to promote a spirocyclization/para‐selective sequence. The C3‐side chain maps onto a range of common drug scaffolds and allows the
Christoph Roblick +5 more
wiley +2 more sources
Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects
Frontiers in Genetics, 2022 Background: Statins are the most popular agents for the primary and secondary prevention of cardiovascular disease; however, the pharmacokinetic parameters and associated genetic factors in the Korean population have not been fully elucidated. This study
Serim Kim +11 more
doaj +1 more source
Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/− Mice
Translational Oncology, 2017 Atorvastatin is widely used to lower blood cholesterol and to reduce risk of cardiovascular disease–associated complications. Epidemiological investigations and preclinical studies suggest that statins such as atorvastatin have antitumor activity for ...
Ming Hong Shen +5 more
doaj +1 more source
Combined Beneficial Effect of Genistein and Atorvastatin on Adipogenesis in 3T3-L1 Adipocytes
Biomolecules, 2021 Genistein (4,5,7-trihydroxyisoflavone) is abundant in various dietary vegetables, especially soybeans, and is known to have not only an estrogenic effect but also an antiadipogenic effect.
Dahae Lee +4 more
doaj +1 more source
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD [PDF]
, 2002 A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.BackgroundIndividuals with chronic renal disease are at high risk of cardiovascular morbidity and mortality, and therefore the management of dyslipidemia is ...
Harris, Kevin P.G. +3 more
core +1 more source
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. [PDF]
PLoS ONE, 2014 OBJECTIVE: Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of
Yuka Keyamura +9 more
doaj +1 more source
Mediators of Inflammation, 2021 Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitor and inhibits cholesterol synthesis. Recently, atorvastatin also showed anti-inflammatory effect in acute lung injury, ameliorating pulmonary gas-blood ...
Lan Wu +4 more
doaj +1 more source
Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
Pharmaceuticals, 2022 The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids.
Jae Hoon Kim +10 more
doaj +1 more source